PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C07D 401/12, 405/14, 401/14, 409/12, A61K 31/445, 31/50, 31/495

(11) International Publication Number:

WO 00/00488

(43) International Publication Date:

6 January 2000 (06.01.00)

(21) International Application Number:

PCT/US99/12821

A1

(22) International Filing Date:

28 June 1999 (28.06.99)

(30) Priority Data:

09/107.983

30 June 1998 (30.06.98) US

(74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US Filed on 09/107,983 (CIP) 30 June 1998 (30.06.98)

(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KOZLOWSKI, Joseph, A. [US/US]; P.O. Box 7391, Princeton, NJ 08543 (US). MCCOMBIE, Stuart, W. [GB/US]; 28 Hanford Place, Caldwell, NJ 07006 (US). TAGAT, Jayaram, R. [US/US]; 133 Boynton Court, Westfield, NJ 07090 (US). VICE, Susan, F. [US/US]; 1144 Sawmill Road, Mountainside, NJ 07092 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report. With amended claims.

(54) Title: MUSCARINIC ANTAGONISTS

$$R^{-1} \stackrel{R^{2}}{\longrightarrow} Z_{R^{4}}$$

$$\xi \stackrel{}{\longrightarrow} \xi \xi \stackrel{}{\longrightarrow} \xi (2) \qquad \xi \stackrel{}{\longrightarrow} \xi (3) \qquad \xi \stackrel{R^{7}}{\longrightarrow} \xi (4)$$

(57) Abstract

Heterocyclic derivatives of di-N-substituted piperazine or 1,4 di-substituted piperidine compounds in accordance with formula (I) (including all isomers, salts and solvates), wherein one of Y and Z is -N- and the other is -N- or -CH-; X is -O-, -S-, -SO-, -SO2- or -CH2-; Q is (1), (2), (3); R is alkyl, cycloalkyl, optionally substituted aryl or heteroaryl; R^1 , R^2 and R^3 are H or alkyl; R^4 is alkyl, cycloalkyl or (4); R^5 is H, alkyl, -C(O)alkyl, arylcarbonyl, -SO2alkyl, aryl-sulfonyl-C(O)Oalkyl, aryloxycarbonyl, -C(O)NH-alkyl or aryl-aminocarbonyl, wherein the aryl portion is optionally substituted; R^6 is H or alkyl; and R^7 is H, alkyl, hydroxyalkyl or alkoxyalkyl; are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of treatment are also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal -
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВЈ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		
1							

10

15

20

25

30

35

MUSCARINIC ANTAGONISTS

BACKGROUND OF THE INVENTION

The present invention relates to heteroaromatic derivatives of di-N-substituted piperazines and 1,4-di-substituted piperidines useful in the treatment of cognitive disorders, pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and to the use of said compounds in combination with acetylcholinesterase inhibitors.

Alzheimer's disease and other cognitive disorders have received much attention lately, yet treatments for these diseases have not been very successful. According to Melchiorre et al. (J. Med. Chem. (1993), 36, 3734-3737), compounds that selectively antagonize M2 muscarinic receptors, especially in relation to M1 muscarinic receptors, should possess activity against cognitive disorders. Baumgold et al. (Eur. J. of Pharmacol., 251, (1994) 315-317) disclose $3-\alpha$ -chloroimperialine as a highly selective m2 muscarinic antagonist.

Logemann et al (Brit. J. Pharmacol. (1961), 17, 286-296) describe certain di-N-substituted piperazines, but these are different from the inventive compounds of the present invention. Furthermore, the compounds of Logemann et al. are not disclosed to have activity against cognitive disorders.

WO 96/26196 discloses benzylpiperidines and piperazines useful as muscarinic antagonists.

40

25

30

SUMMARY OF THE INVENTION

The present invention relates to compounds according to the structural formula I,

$$R-X-Q$$

$$R^{1}$$

$$R^{2}$$

$$Z$$

$$R^{4}$$

5 including all stereoisomers and pharmaceutically acceptable salts and solvates thereof,

wherein one of Y and Z is -N- and the other is -N- or -CH-;

Q is
$$\begin{cases} -\frac{1}{N} - \frac{1}{2}, \frac{1}{N-N} - \frac{1}{2}, \frac{1}{N-N} \end{cases}$$
 or $\begin{cases} -\frac{1}{N} - \frac{1}{2}, \frac{1}{N-N} - \frac{1}{2}, \frac{1}{N-N} - \frac{1}{2}, \frac{1}{N-N} - \frac{1}{2}, \frac{1}{N-N} - \frac{1}{N-N}$

R is (C_1-C_{20}) alkyl, (C_3-C_{12}) cycloalkyl, aryl, R⁸-aryl or heteroaryl; R¹, R² and R³ are independently selected from the group consisting of H and (C_1-C_{20}) alkyl;

 R^4 is (C_1-C_{20}) alkyl, (C_3-C_{12}) cyclolalkyl or

15 R⁵ is H, (C_1-C_{20}) alkyl, $-C(O)(C_1-C_{20})$ alkyl, R⁹-arylcarbonyl, $-SO_2(C_1-C_{20})$ alkyl, R⁹-arylsulfonyl $-C(O)O(C_1-C_{20})$ alkyl, R⁹-aryloxy-carbonyl, $-C(O)NH-(C_1-C_{20})$ alkyl or R⁹-arylaminocarbonyl;

 R^6 is H or (C_1-C_{20}) alkyl;

 R^7 is H, (C_1-C_{20}) alkyl, hydroxy (C_1-C_{20}) alkyl or (C_1-C_{20}) -

20 alkoxy(C_1 - C_{20})alkyl;

 R^8 is 1-3 substituents independently selected from the group consisting of H, (C_1-C_{20}) alkyl, halogen, hydroxy, (C_1-C_{20}) alkoxy or hydroxy(C_1-C_{20})alkyl, or two adjacent R^8 groups may be joined to form a (C_1-C_2) alkylenedioxy group; and

 R^9 is 1-3 substituents independently selected from the group consisting of H, (C_1-C_{20}) alkyl, halogen, amino or (C_1-C_{20}) alkylamino.

In a preferred group of compounds Z is N.
In another preferred group of compounds R is R⁸-substituted phenyl, especially 3,4-methylenedioxyphenyl, 3-methylphenyl, 3-chlorophenyl or 4-methoxyphenyl.

X is preferably -CH₂- or -SO₂-.

Q is preferably
$$\begin{cases} N - N \end{cases}$$
 or $\begin{cases} N - N \end{cases}$

R¹ and R² are each preferably H; R³ is preferably H or CH₃. In another group of preferred compounds, R⁴ has the formula

5

10

15

20

25

wherein R^7 is H or CH_3 ; R^6 is H: and R^5 is R^9 -arylcarbonyl, preferably R^9 -(1-naphthyl)-C(O)-, especially wherein R^9 is fluoro, or R^9 -phenyl-C(O)-, especially wherein R^9 is 2-methyl, 2-amino, 2-bromo or 2-chloro.

Another aspect of the invention is a pharmaceutical composition which comprises an effective amount of a compound having structural formula I as defined above in combination with a pharmaceutically acceptable carrier.

Another aspect of the invention is the use of a compound formula I for the preparation of a pharmaceutical composition useful in the treatment of cognitive disorders and neurodegenerative diseases such as Alzheimer's disease.

Another aspect of this invention is a method for treating a cognitive or neurodegenerative disease comprising administering to a patient suffering from said disease an effective amount of a compound of formula I.

DETAILED DESCRIPTION

Except where stated otherwise the following definitions apply throughout the present specification and claims. These definitions apply regardless of whether a term is used by itself or in combination with other terms. Hence the definition of "alkyl" applies to "alkyl" as well as the "alkyl" portions of "alkoxy", etc.

Alkyl represents a straight or branched saturated hydrocarbon chain having 1 to 20 carbon atoms, more preferably 1 to 8 carbon atoms.

Cycloalkyl represents a saturated carbocyclic ring having 3 to 12 carbon atoms.

Halogen represents fluoro, chloro, bromo or iodo. Aryl represents phenyl or naphthyl.

10

15

20

25

30

35

Heteroaryl refers to 5- to 10-membered single or benzofused aromatic rings comprising 1 to 4 heteroatoms independently selected from the group consisting of -O-, -S- and -N=, provided that the rings do not include adjacent oxygen and/or sulfur atoms. Examples of single-ring heteroaryl groups are pyridyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazinyl, pyrimidyl, pyridazinyl and triazolyl. Examples of benzofused heteroaryl groups are indolyl, quinolyl, benzothienyl (i.e., thianaphthenyl), benzimidazolyl, benzofuranyl, benzoxazolyl and benzofurazanyl. N-oxides of nitrogen-containing heteroaryl groups are also included. 2-, 3-, 5- and 6-positional isomers are contemplated, e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl and 6-pyridyl.

When a variable appears more than once in the structural formula, for example R⁸, the identity of each variable appearing more than once may be independently selected from the definition for that variable.

Compounds of this invention may exist in at least two stereo configurations based on the asymmetric carbon to which R¹ is attached, provided that R¹ and R² are not identical. Also within formula I there are numerous other possibilities for stereoisomerism. All possible stereoisomers of formula I are within the scope of the invention.

Compound of formula I can exist in unsolvated as well as solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for purposes of this invention.

A compound of formula I may form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as

dilute aqueous sodium hydroxide, potassium carbonate, ammonia or sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for purposes of the invention.

Compounds of formula I may be produced by processes known to those skilled in the art as shown by the following reaction schemes:

- 10 Compounds of formula IA, wherein Y is N, Z is N, Q is thienylidene, X is SO₂, R⁴ is substituted piperidinyl and R¹ and R² are each H, can be prepared by reacting thiophenecarboxaldehyde with a 4-N-BOC-piperazine in the presence of sodium triacetoxy borohydride and acetic acid, followed by reaction with n-butyllithium and R-sulfonyl-
- 15 fluoride. The BOC group is removed with acid and the resultant piperazine is reacted with a piperidone and sodium triacetoxy borohydride and acetic acid to obtain a compound of formula IA. Scheme 2:

10

Compounds of formula IB, wherein Y is N, Q is pyridazinylidene, X is SO₂, R⁴ is substituted piperidinyl and R¹ and R² are each H, can be prepared by reacting an alkyl 6-chloropyridazine-3-carboxylate with a compound of the formula RSO₂Na, reducing the resultant carboxylate to the aldehyde, and coupling an N-BOC-piperidyl substituted piperidine or piperazine compound to the aldehyde. The BOC protecting group is removed by treatment with acid, and the resultant piperidinyl compound is reacted with a compound of the formula R⁵COCI to obtain the desired compound of formula IB.

Scheme 3:

10

15

25

Compounds of formula IC, wherein Y is CH, Q is pyridazinylidene, X is SO₂, R⁴ is substituted piperidinyl and R¹ and R² are each H, can be prepared by reacting 3,6-diiodopyridazine with a compound of the formula RSH in the presence of a strong base such as diazabicyclo-undecane (DBU), followed by oxidation of the thiol to the sulfonyl by treatment with a reagent such a m-chloroperbenzoic acid. 4-[(4-Methylene)-piperdin-1-yl]-piperidine is treated with a reagent such as 9-borabicyclo[3.3.1]nonane (9-BBN) and the resulting trialkylborane is then reacted with the pyridazine and a palladium (0) catalyst. The BOC protecting group is removed by treatment with acid, and the resultant piperidinyl compound is reacted with a compound of the formula R⁵COCI to obtain the desired compound of formula IC.

To prepare compounds of formula ID, wherein Y is CH, Q is pyridazinylidene, X is S, R⁴ is substituted piperidinyl and R¹ and R² are each H, the R-S-iodopyridazine is reacted with a 4-methylenepiperidine in the presence of a palladium (0) catalyst as described above, followed by reaction with an N-BOC-4-piperidone. The BOC-protecting group is removed and the R⁵ substituent is attached as described above for preparing compounds of formula IC.

20 Scheme 4:

Compounds of formula IE, wherein Y is N, Q is pyridylidene, X is SO₂, R⁴ is substituted piperidinyl and R¹ and R² are each H, can be prepared by reacting a halo-substituted nicotinic acid with a compound of the formula RSH, then reducing the acid to the corresponding alcohol and oxidizing the thiol to the corresponding sulfonyl. The resultant compound is then coupled with an N-BOC-piperidyl substituted

10

piperidine as described for Scheme 2, and the R⁵substituent is attached as described for Scheme 3.

Scheme 5:

Compounds of formula IF, wherein Y is N, Q is pyridylidene, X is SO₂, R⁴ is substituted piperidinyl and R¹ and R² are each H, can be prepared by reacting 2,5-dibromopyridine with a compound of the formula RSO₂Na and n-butyllithium, followed by coupling with an N-BOC-piperidyl substituted piperidine or piperazine, removing the BOC protecting group as described in Scheme 2 and reacting with R⁵COCl as described in Scheme 3 to obtain the desired compound.

Scheme 6:

Br DMF
$$O_2S$$
 O_2S O_2S

Compounds of formula IG, wherein Y is CH, Q is pyridylidene, X is SO₂, R⁴ is substituted piperidinyl and R¹ and R² are each H, can be prepared by reacting 2,5-dibromopyridine with a compound of the formula RSO₂Na, then treating the resultant compound in a manner similar to that described in Scheme 3 for preparing compounds of formula IC.

20 <u>Scheme 6</u>:

10

15

20

25

Compounds of formula IH, , wherein Y is N, Q is pyridylidene, X is SO_2 , R^4 is substituted piperidinyl, R^1 is methyl and R^2 is H, are prepared by converting 6-chloronicotinic acid to the corresponding chloro-ketone via the Weinreb amide. The chloro-ketone is reacted with RSO_2Na in hot DMF, followed by enantioselective reduction using the (S)-2-methyl oxaborolidine catalyst and borane-methyl sulfide to furnish the chiral alcohol which is enriched in the R-enantiomer. The mesylate derived from the alcohol is reacted with a piperazino piperidine in refluxing acetonitrile, and removal of the BOC protecting group followed by coupling to various aromatic acids (R^5CO_2H) under standard conditions provides the target compounds IH.

The above reactions may be followed if necessary or desired by one or more of the following steps; (a) removing any protective groups from the compound so produced; (b) converting the compound so-produced to a pharmaceutically acceptable salt, ester and/or solvate; (c) converting a compound in accordance with formula I so produced to another compound in accordance with formula I, and (d) isolating a compound of formula I, including separating stereoisomers of formula I.

Based on the foregoing reaction sequence, those skilled in the art will be able to select starting materials needed to produce any compound in accordance with formula I.

The compounds of formula I exhibit selective m2 and/or m4 muscarinic antagonizing activity, which has been correlated with

10

15

20

25

30

pharmaceutical activity for treating cognitive disorders such as Alzheimers disease and senile dementia.

The compounds of formula I display pharmacological activity in test procedures designated to indicate m1 and m2 muscarinic antagonist activity. The compounds are non-toxic at pharmaceutically therapeutic doses. Following are descriptions of the test procedures.

MUSCARINIC BINDING ACTIVITY

The compound of interest is tested for its ability to inhibit binding to the cloned human m1, m2, m3, and m4 muscarinic receptor subtypes. The sources of receptors in these studies were membranes from stably transfected CHO cell lines which were expressing each of the receptor subtypes. Following growth, the cells were pelleted and subsequently homogenized using a Polytron in 50 volumes cold 10 mM Na/K phosphate buffer, pH 7.4 (Buffer B). The homogenates were centrifuged at 40,000 x g for 20 minutes at 4°C. The resulting supernatants were discarded and the pellets were resuspended in Buffer B at a final concentration of 20 mg wet tissue/ml. These membranes were stored at -80°C until utilized in the binding assays described below.

Binding to the cloned human muscarinic receptors was performed using $^3\text{H-quinuclidinyl}$ benzilate (QNB) (Watson et al., 1986). Briefly, membranes (approximately 8, 20, and 14 $\,\mu\text{g}$ of protein assay for the m1, m2, and m4 containing membranes, respectively) were incubated with $^3\text{H-QNB}$ (final concentration of 100-200 pM) and increasing concentrations of unlabeled drug in a final volume of 2 ml at 25°C for 90_minutes. Non-specific binding was assayed in the presence of 1 $\,\mu\text{M}$ atropine. The incubations were terminated by vacuum filtration over GF/B glass fiber filters using a Skatron filtration apparatus and the filters were washed with cold 10mM Na/K phosphate butter, pH 7.4. Scintillation cocktail was added to the filters and the vials were

Scintillation cocktail was added to the filters and the vials were incubated overnight. The bound radioligand was quantified in a liquid scintillation counter (50% efficiency). The resulting data were analyzed for IG₅₀ values (i.e. the concentration of compound required to inhibit binding by 50%) using the EBDA computer program (McPherson, 1985).

Affinity values (K_i) were then determined using the following formula (Cheng and Prusoff, 1973);

$$K_{i} = \frac{IC_{50}}{1 + \frac{\text{concentration of radioligand}}{\text{affinity (K}_{D}) \text{ of radioligand}}}$$

Hence, a lower value of Ki indicates greater binding affinity.

To determine the degree of selectivity of a compound for binding the m2 receptor, the K_i value for m1 receptors was divided by the K_i value for m2 receptors. A higher ratio indicates a greater selectivity for binding the m2 muscarinic receptor.

For the compounds of this invention, the following range of muscarinic antagonistic binding activity was observed (not all compounds were tested for m3 and m4 binding activity):

10

15

20

25

5

m1: 96 nM to 1860 nM

m2: 1.5 nM to about 1400nM, preferably 1.5 nM to about 600 nM

m3: 59 nM to 2794 nM

m4: 28 nM 638 nM

A preferred compound of this invention, the compound of Example 39, has an average m1 antagonist binding activity of 917 and an average m2 antagonist binding activity of 1.5.

For preparing pharmaceutical compositions from the compounds of formula I, pharmaceutically acceptable, inert carriers are admixed with the active compounds. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be one or more substances which may also act as dilutents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it may also be an encapsulating material.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.

30

- Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parentertal administration. Such liquid forms include solutions, suspensions and emulsions. These particular solid form preparations

10

15

20

25

30

35

are most conveniently provided in unit dose form and as such are used to provide a single liquid dosage unit.

The invention also contemplates alternative delivery systems including, but not necessarily limited to, transdermal delivery. The transdermal compositions can take the form of creams, lotions and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation such as packeted tablets, capsules and powders in vials or ampules. The unit dosage form can also be a capsule, cachet or tablet itself, or it may be the appropriate number of any of these in a packaged form.

The quantity of active compound in a unit dose preparation may be varied or adjusted from 1 mg to 100 mg according to the particular application and the potency of the active ingredient and the intended treatment. This would correspond to a dose of about 0.001 to about 20 mg/kg which may be divided over 1 to 3 administrations per day. The composition may, if desired, also contain other therapeutic agents.

The dosages may be varied depending on the requirement of the patient, the severity of the condition being treating and the particular compound being employed. Determination of the proper dosage for a particular situation is within the skill of those in the medical art. For convenience, the total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.

The invention disclosed herein is exemplified by the following examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures may be apparent to those skilled in the art. As used herein, tetrahydrofuran is THF, dimethylformamide is DMF, ethyl acetate is EtOAc, trifluoroacetic acid is TFA, dimethylsulfoxide is DMSO, m-chloro-perbenzoic acid is MCPBA, triethyl amine is Et₃N, diisopropyl ethylamine is iPr₂EtN, 9-borabicyclo[3.3.1]-nonane is 9-BBN, and 1,1'-bis(diphenyl-phosphino)-

15

20

ferrocene palladium (II) chloride is Pd(dppf)Cl₂. In the examples, Ar in the structures is 3-methylphenyl; Ar¹ is 4-methyloxyphenyl.

Example 1

5 Reaction Scheme:

2
$$\xrightarrow{\text{MCPBA}}$$
 $\xrightarrow{\text{ArO}_2\text{S}}$ $\xrightarrow{\text{N}}$ $\xrightarrow{\text{N}}$

Step 1A: To a cooled (0°C) mixture of DMF (25 mL) and NaH (1.00 g of a 60% suspension in oil) was added, slowly dropwise, m-toluene thiol (3.10 g). After the addition was complete, the cooling bath was removed, the resulting mixture was stirred for 1 h at room temperature (RT), 6-bromo-nicotinic acid (5.00 g) was added all at once and the resulting mixture was heated at reflux for 6 h. After cooling to RT, the mixture was poured into cold water (250 mL) and the resulting solid was collected, washed with water and dried to give the desired product **1** (4.91 g) in 80% yield.

To a solution of sulfide 1 (0.50 g) and THF (2 mL) was added BH₃ DMS (0.61 mL), dropwise. The resulting solution was stirred for 1 h at RT, diluted with EtOAc and ice and stirred for 5 min. The pH was adjusted to 11 with 2 N NaOH and the resulting mixture was extracted with EtOAc (3 X 10 mL). The EtOAc extracts were dried with brine, then over MgSO₄, filtered and evaporated to give a light colored foam 2 (0.44 g), which was used without further purification.

- Step 1B: To a cooled (0°C) solution of 2 and CH_2CI_2 was added MCPBA (671 mg of technical grade) in three portions over 10 min. After warming to RT and stirring for 12 h, the resulting mixture was diluted with CH_2CI_2 (5 mL) and MCPBA (300 mg) was added. After 4 h at RT, the resulting mixture was diluted with CH_2CI_2 , washed successively with cold 1 N NaOH, water and brine and dried over MgSO₄. After filtration and evaporation, the crude oil was purified by preparative plate chromatography (2000 μ M plate; silica adsorbent; 2:1 EtOAc:hexane eluant) to give the product 3 as a white solid (0.22 g).
- Step 2: To a cooled (0°C) solution of sulfone 3 (0.20g), CH₂Cl₂ (7.5 mL) and Et₃N (0.13 mL) was added CH₃SO₂Cl (0.061 mL). The resulting solution was stirred for 5 min at 0°C and 30 min at RT and then washed successively with water, 1 N NaOH and brine and dried over MgSO₄. After filtration and evaporation, the resulting oil was dissolved in CH₃CN (0.68 mL) and iPr₂EtN (0.14 mL) and the piperazine (0.29 g) was added. The resulting solution was stirred for 12 h at which time CH₃CN (0.5 mL) was added and stirring was continued for 2 days. The
- partitioned between CH₂Cl₂ and water. The pH was adjusted to 11 with 2 N NaOH, the CH₂Cl₂ layer was removed and the aqueous layer extracted with CH₂Cl₂ (3 X 3 mL). The combined organic extracts were dried with brine and over MgSO₄, filtered and evaporated to give a crude gum which was purified by preparative plate chromatography (2 X 2000 μM plate; silica adsorbent; 95:5 EtOAc:Et₃N eluant) to give the

CH₃CN was removed in vacuo and the resulting crude mixture was

- 25 product **4a** as a foam (0.29 g) in 82 % yield. HRMS: calc'd: $M.H^{+}$: $C_{28}H_{41}N_{4}O_{4}S$: 529.2849; measured: 529.2840.
 - **Step 3:** To a cooled (0°C) solution of **4a** (0.27 g) and CH_2CI_2 (2.1 mL) was added TFA (0.42 mL) and water (9 μ L). The resulting solution was stirred at RT for 2 h; the volatile materials were removed in vacuo;
- 30 CH₂Cl₂ (20 mL) was added; the pH was adjusted to 11 with 10 % NaOH and the organic layer was removed. After drying (with brine and MgSO₄) and evaporation, the product **4** was collected as a white foam (0.16 g) in 71 % yield.
- Step 4: The product of Step 3, 4 (29 mg), was mixed with CH₃CN (0.4 mL), iPr₂EtN (0.15 mL) and N-methyl isatoic anhydride (48 mg). After

10

15

20

25

stirring for 2 days at RT, the resulting mixture was diluted with EtOAc (15 mL) and washed with cold water, brine and dried over MgSO₄, then filtered and evaporated to give a crude solid which was further purified by preparative plate chromatography (500 μ M plate; silica adsorbent; 95:5 EtOAc:Et₃N eluant) to give the product as a foam (28 mg) in 75 % yield. HRMS (as the HCl): calc'd: M·H⁺: C₃₁H₄₀N₅O₃S: 562.2852; measured: 562.2850; mp (HCl): 144-148°C (with decomposition).

Example 2

The intermediate 4 (29 mg) from Example 1 was dissolved in CH₂Cl₂ (1.0 mL) and 2.0 M Na₂CO₃ (0.2 mL) was added. The resulting mixture was cooled to 0°C and CH₃(CH₂)₂SO₂Cl (7.62 μL) was added. The mixture was stirred for 5 min at 0°C and 15 min at RT then MgSO₄ was added. The CH₂Cl₂ layer was removed and the solids were extracted with CH₂Cl₂ (3 X 3 mL), the CH₂Cl₂ extracts were combined, dried with MgSO₄, filtered and evaporated to give a crude foam which was purified by preparative plate chromatography (500 μM plate; silica adsorbent; 95:5 EtOAc:Et₃N eluant) to give the product as a foam (33 mg) in 90 % yield. HRMS (as the HCl): calc'd: M·H⁺: C₂₆H₃₈N₄O₄S₂: 535.2413; measured: 535.2405; mp (HCl): 146-150°C (with decomposition).

Example 3

Reaction Scheme:

Br
$$\stackrel{\text{Br}}{\searrow}$$
 $\stackrel{\text{1. nBuLi}}{\searrow}$ $\stackrel{\text{CHO}}{\searrow}$ $\stackrel{\text{CHO}}{\searrow}$ $\stackrel{\text{SO}_3\text{Na}}{\searrow}$ $\stackrel{\text{CHO}}{\searrow}$ $\stackrel{\text{CH$

10

15

30

Step 1: To a cooled (-90°C) solution of 2,5-dibromopyridine (10 g) and THF (264 mL) was added, dropwise, nBuLi (16.9 mL of a 2.5 M solution in hexanes) and the resulting solution was stirred for 5 min. DMF (3.27 mL) was added dropwise and the resulting solution was warmed to -50°C and stirred for 15 min at that temperature. The reaction solution was poured onto ice and extracted with EtOAc (3 X 75 mL). The combined EtOAc extracts were dried over MgSO₄, filtered and evaporated to give 7.8 g of crude material which was purified by silica gel chromatography (4:1 hexane:EtOAc as eluant). After combining the desired fractions and evaporating the solvents, the desired aldehyde 5 was isolated as a solid (0.89 g) in 11% yield.

Step 2: A mixture of **5** (0.20 g), DMSO (1.0 mL) and 3,4-methylene dioxy benzene sulfinate, sodium salt (0.19 g) was heated at 40° C for 21 h then cooled and poured into water (10 mL). The resulting solution was made basic (pH = 11) with 2 N NaOH and extracted with EtOAc (3 X 5 mL). The combined extracts were dried with brine and MgSO₄, filtered and evaporated to give a crude oil which was purified by silica gel chromatography (2:1 hexane:EtOAc eluant). The desired fractions were combined and evaporated to give the product **6** (0.10 g) in 33% yield.

Step 3: To a solution of 6 (0.10 g), the piperazine 7 (0.23 g) and CH₂Cl₂ (2.5 mL) was added NaB(OAc)₃H (0.11 g) and the resulting solution was stirred for 1.5 h. The reaction was diluted with CH₂Cl₂ and made basic with 2 N NaOH. The CH₂Cl₂ layer was removed and the aqueous layer was extracted with CH₂Cl₂ (2 X 5 mL). The organic extracts were combined, washed with water, brine and dried over

extracts were combined, washed with water, brine and dried over MgSO₄, then filtered and evaporated to give a crude oil which was purified by preparative plate chromatography (2000 µM plate; silica adsorbent; 1:1 CH₂Cl₂:

acetone eluant) to give the product as a foam (95 mg) in 47 % yield. mp(HCl): decompostion above 225°C.

Example 4

10

15

Reaction scheme:

$$\begin{array}{c|c}
 & CH_2OH \\
\hline
 & MnO_2 \\
\hline
 & S \\
\hline
 & N \\
 & 9 \\
\end{array}$$
CHO

$$\begin{array}{c}
 & 7 \\
\hline
 & NaB(OAc)_3H
\end{array}$$
Ex. 4

Step 1: The carbinol intermediate **8** was prepared by the method outlined for Step 1A of Example 1, but m-toluene thiol was replaced with iso-propyl thiol.

Step 2: The carbinol intermediate **8** (50 mg) was dissolved in CHCl₃ (1.0 mL) and MnO₂ (165 mg) was added. The resulting mixture was heated at reflux for 2 days and the solid reaction mixture was then cooled, taken up in CHCl₃ (10 mL) and filtered through Celite. The solids were washed with CHCl₃ (3 X 10 mL), the organic extracts were combined, dried over MgSO₄, filtered and evaporated to give the desired aldehyde **9** (42 mg) in 86 % yield.

Step 3: 9 was subjected to the same reaction conditions as outlined in Example 3, Step 3, using piperazine intermediate **7**, to give the title compound (0.12 g) in 50% yield. mp(HCl): decomposition above 197°C.

Example 5

Reaction scheme:

Br NBOC
$$Ar^1SO_2$$
 NBOC Ar^1SO_2 NBOC Ar^1

10

15

30

N-methyl isatoic anhydride Ex. 5

Step 1: A mixture of 2,5-dibromopyridine (3.7 g), para-methoxy benzene sulfinate, sodium salt (3.0 g) and DMF (8.0 mL) was heated at reflux for 48 h, cooled and partitioned between water and EtOAc. The aqueous layer was checked to be basic (pH >8) and was extracted with EtOAc (2 X 75 mL). The organic extracts were combined, washed with water and brine and dried over MgSO₄. After filtration and evaporation, the crude solid (3.5 g) was chromatographed on silica gel (gradient: 8:1 hexanes: EtOAc; 4:1 hexanes:EtOAc; 1:1 hexanes:EtOAc) to give, after evaporation of the appropriate fractions, **10** (0.27 g) in 5.3% yield. mp: 104-107°C.

Step 2: To a degassed, cooled (0°C) sample of **11** (1.7 g) was added 9-BBN (17.5 mL of a 0.5 M in THF). The cooling bath was removed and the solution was stirred for 1.5 h at RT. The resulting solution was added, at RT, to a mixture of the sulfone **10** (0.27 g), Pd(dppf)Cl₂ (20 mg), triphenyl arsine (25 mg), DMF (2.0 mL), water (0.18 mL) and Cs_2CO_3 (0.33 g). The resulting mixture was heated at 60°C for 3 h 45 min. After cooling to RT and pouring into water, the pH was adjusted to 11 with 10 % NaOH and mixture was extracted with EtOAc (3 X 25 mL).

- The combined organic extracts were dried with brine and MgSO₄, filtered and evaporated to give a crude which was further purified by preparative plate chromatography (2000 μM plate; silica adsorbent; 1:1 EtOAc:hexanes eluant) to give the product **12** as a white foam (0.28 g) in 77 % yield.
- 25 **Step 3:** 12 was treated as described in Example 1, Step 3. The product 13 was isolated as a foam (0.11 g) in 82 % yield.
 - **Step 4:** 13 was treated as described in Example 3, Step 3, except one equivalent of acetic acid was added and N-BOC-piperidone was used as the carbonyl component. After work up, the crude was further purified by preparative plate chromatography (2000 μM plate; silica adsorbent; 95:5_EtOAc:Et₃N eluant) to give **14** as an oil (0.21 g).
 - **Step 5:** 14 was treated as described in Example 1, Step 3, to give 15 as a white foam (53 mg) in 41% over two steps. HRMS: calc'd: $M'H^{\dagger}$: $C_{23}H_{22}N_3O_3S$: 430.2164; measured: 430.2160.

10

Step 6: 15 was treated as described in Example 1, Step 4 and was purified by preparative plate chromatography (500 μM plate; silica adsorbent; 95:5 EtOAc:Et₃N eluant) to give the title compound as an oil (33 mg) in 96% yield. mp(HCl): 108-110°C (with decomposition).

Example 6

The intermediate **15** from Example 5, Step 6 was treated as described in Example 2, except the sulfonyl chloride was replaced with 4-fluoro-naphthoyl chloride and the crude was purified by preparative plate chromatography (500 μ M plate; silica adsorbent; 95:5 EtOAc:Et₃N eluant) to give the title compound as an oil (33 mg) in 96% yield. mp(HCl): decomposition above 184°C.

Example 7

15 Reaction scheme:

20

- **Step 1:** To CH_2CI_2 (50 mL), add 4-N-BOC-2-(R)-methypiperazine (1 g, 4.9 mmol), thiophene-2-carboxaldehyde (0.46 mL), NaBH(OAc)₃ (1.5 g, 7.5 mmol) and acetic acid (0.25 mL), and stir overnight at RT. Add CH_2CI_2 (100 mL) and wash with saturated NaHCO₃ and brine. The organic phase was dried over Na_2SO_4 and concentrated on a rotary evaporator. The crude product **16** was purified on a silica column eluted with EtOAc.
- **Step 2: 16** was dissolved in THF (15 mL), then cooled in a dry ice/acetone bath where n-BuLi (0.64 mL, 2.5 M) was added dropwise.
- After 15 min the temperature was raised to 0°C, stirred for 30 min, then recooled to -78°C where 4-methoxybenzenesulfonyl fluoride (0.3 g, 1.6 mmol) was added. After 10 min, the temperature was raised to 0°C for 15 min, then to RT for 15 min. After quenching with saturated NaHCO₃, EtOAc was added and the organic phase washed with brine and dried over Na₂SO₄. The crude product 17 was purified on a silica column using 2:1 hexane:EtOAc.
 - **Step 3: 17** (0.22 g) was dissolved in EtOAc (4 mL) and 6 N HCl (0.8 mL) was added with vigorous stirring. After 2h the reaction was neutralized with saturated NaHCO₃ solution. CH₂Cl₂ (50 mL) was added and the organic phase separated and dried over NaHCO₃. After concentration on a rotary evaporator, the crude product **18** was used without purification.
- Step 4: N-BOC-piperidone (0.09 g, 0.43 mmol), 18 (0.16 g, 0.43 mmol), NaBH(OAc)₃ (0.14 g, 0.65 mmol) and acetic acid (0.025 mL) were added to CH₂Cl₂ (5 mL), and the mixture was stirred overnight at -RT. CH₂Cl₂ (10 mL) was added and washed with saturated NaHCO₃, and brine. The organic phase was dried over Na₂SO₄ and concentrated on a rotary evaporator. The crude product 19 was purified on a silica column using EtOAc as eluent.
- 30 **Step 5: 19** (0.2 g) was dissolved in EtOAc (3 mL) and 6 N HCl (0.5 mL) added with vigorous stirring. After 2h, the reaction was neutralized with saturated NaHCO₃ solution. CH₂Cl₂ (15 mL) was added and the organic phase separated and dried over NaHCO₃. After concentration on a rotary evaporator the crude product **20** was used without purification.

10

Step 6: 20 (0.03 g) was dissolved in CH_2CI_2 (1 mL) followed by addition of Et_3N (0.011 mL), and o-toluoyl chloride (0.007 mL). After 1h at RT the solution was transferred directly to a prep. TLC plate and eluted with EtOAc. The major UV band (Rf = 0.1) was collected and extracted with 10% $CH_3OH/$ EtOAc. Filtration and evaporation gave the purified material. The HCl salt was prepared by dissolving the product in a minimum amount of EtOAc followed by additon of dry HCl/ether. The precipitate was collected with a centrifuge, washed with ether and dried under vacuum to obtain the title compound. mp 190-192°C (decomposition).

Example 8

Step 1: Heat a mixture of ethyl 6-chloropyridazine-3-carboxylate 21

(1.8 g), sodium (3,4-methylenedioxy)-benzenesulfonate (2 g) and DMSO

(20 mL) at 120-125°C for 8 h. Cool and add to water (100 mL) stir 10

min, collect, wash well with water and dry at RT in high vacuum to give compound 22 as a white solid (2.0 g), mp 153-155°C.

10

20

25

Step 2: To an ice-cooled solution of compound **22** (0.6 g) in dry THF (40 mL) add 1M diisobutylaluminum hydride in toluene (3.6 mL), stir for 5 min., add CH_2CI_2 (100 mL) and then excess iced water. Stir and add 2N HCI (20 mL) to dissolve the solids. Extract with CH_2CI_2 , dry over $MgSO_4$ and filter on a small pad of silica gel, washing with 20% EtOAc in CH_2CI_2 . Evaporate to obtain the aldehyde **23** (0.42 g) as a yellow foam, suitable for the next step.

Step 3: Stir a mixture of compound **23** (0.42 g), 1-(1-tertbutoxy-carbonyl-piperidin-4-yl)-piperazine (0.42 g) and NaBH(OAc)₃ (0.42 g) in CH_2CI_2 (30 mL) at RT for 6 h. Wash with 1N aqueous NaOH solution, dry over MgSO₄ and evaporate. Isolate the product by silica gel chromatography with a gradient of EtOAc in CH_2CI_2 , and evaporate the pure fractions to obtain compound **24** as a white foam (0.58 g).

Step 4: Stir the product of Step 3 in EtOAc (20 mL) and conc. HCl (5 mL) for 2 h. at RT. Basify with excess 2N NaOH with ice cooling, extract with several portions of CH₂Cl₂, dry over K₂CO₃ and evaporate to obtain the amine **25** as a pale yellow foam (0.35 g).

Step 5: Stir for 20 h. at RT a mixture of compound **25** (0.04 g), otoluoyl chloride (0.04 g), CH₂Cl₂ (10 mL) and 1N aqueous NaOH (10 mL). Separate the organic phase, dry and evaporate. Dissolve the residue in CH₂Cl₂ (1 mL) and add to ether (15 mL) containing HCldioxan (4M; 0.25 mL). Centrifuge and wash by suspension-centifugation 3x with ether, then dry under a nitrogen stream, and finally at high vac./RT to give the hydrochloride of the title compound as a cream powder (0.035 g), mp 195-198°C with decomposition.

Example 9

Use the procedure of Example 8, replacing the toluoyl chloride with 1-naphthoyl chloride (0.05 g) to obtain the final hydrochloride (0.042 g) of the title compound as a white powder, mp 175-180°C with decomposition.

10

Stir for 20 h. at RT a mixture of compound **25** from Example 8 (0.058 g), DMF (2 mL), iPr₂EtN (0.1 mL), hydroxybenzotriazole (HOBT) (0.038 g), 3-methylpicolinic acid hydrochloride (0.036 g) and N-ethyl-N'-(dimethylaminopropyl)-carbodiimide hydrochloride (EDCI) (0.055 g). Extract in EtOAc-aq. NaHCO₃, wash with several portions of 5% aq. NaCl, dry over MgSO₄, evaporate and pump at high vacuum to remove any residual DMF. Precipitate the HCl salt as described in Example 8 to obtain the title compound (0.035 g) as a hygroscopic powder with a broad melting range.

Use the procedure of Example 8, but replace the toluoyl chloride with 2-bromobenzoyl chloride (0.05 g) to obtain the hydrochloride of the title compound (0.040 g) as a white powder, mp 198-203°C with decomposition.

20 Reaction scheme:

30

Step 1: Stir diiodopyridazine (3.4 g) and p-methoxybenzenethiol (1.4 g) in CH₂Cl₂ (40 mL) and add diazabicycloundecane (DBU; 2 mL)
dropwise. Stir for 1.5 h., dilute with hexanes (50 mL) and chromatograph on silica gel, eluting with a gradient of CH₂Cl₂ in hexanes. Evaporate the product fractions and recrystallize from etherhexanes to give pure 26 (1.65 g), mp 113-114°C.

Step 2: Stir 1-(t-butoxycarbonyl)-4-methylenepiperidine (0.86 g) in 0.5M 9-BBN/THF (9 mL) ar RT for 1 h. under N₂. Add **26** (1.33 g), DMF (9 mL), water (1 mL), triphenylarsine (0.10 g), Pd(dppf)Cl₂ complex (0.10 g) and Cs₂CO₃ (2.0 g) and heat at 90°C for 2.5 h. Extract in water-CH₂Cl₂, dry over MgSO₄ and evaporate, then pump to remove DMF. Chromato-graph on silica gel, eluting with a gradient of ether in CH₂Cl₂.

15 Combine and evaporate pure product fractions to give **27** (1.13 g), mp 90-92°C.

Step 3: Stir compound 27 (0.5 g) in TFA (4 mL), water (0.25 mL) and CH₂Cl₂ (2 mL) at RT for 1 h., evaporate, add 1N NaOH and extract with several portions of CH₂Cl₂. Dry over MgSO₄, evaporate and to the residue add CH₂Cl₂ (6 mL), 1-Boc-4-piperidinone (0.33 g) NaBH(OAc)₃ (0.4 g). Stir 24 h., wash with 1N NaOH, dry, evaporate and chromatograph on silica gel with a gradient of CH₃OH in CH₂Cl₂. Evaporate the pure fractions to give 28 as a foam (0.44 g).

Step 4: Stir 28 in TFA (4 mL) for 2 h., evaporate and workup in 1N NaOH with CH₂Cl₂ extractions. Dry and evaporate to obtain the product 29 as a pale yellow solid (0.33 g). HRMS found: 399.2220; theory for MH⁺ = 399.2219.

Step 5: Stir **29** (0.04 g) in CH₂Cl₂ (3 mL) with 1N NaOH (3 mL) and 6-chloronaphthoyl chloride (0.05 g) for 0.5 h. Separate the organic phase, add CH₃OH (20 mL) and evaporate. Isolate the product by preparative t.l.c., eluting with EtOAc, and convert to the HCl salt as described

15

20

Example 8. The title compound (0.025 g) was obtained as a pale yellow powder, mp 180-190°C with decomposition.

5 Reaction scheme:

Step 1: Stir the sulfide **26** (0.24 g) in CH_2CI_2 (5 mL) and add mCPBA (85%; 0.4 g). Stir at RT for 3 h., dilute with CH_2CI_2 and wash with aqueous solutions of Na_2SO_3 and then $NaHCO_3$. Dry, evaporate and recrystallize from CH_2CI_2 -hexanes to give the product **30** as white crystals (0.23 g), mp 193-196°C.

Step 2: Heat a solution of 1-(tert-butoxycarbonyl)-4-[(4-methylene)-piperdin-1-yl]-piperidine (0.20 g) in 0.5M 9-BBN-THF (1.6 mL) under nitrogen at 60-70°C for 2 h., then dilute with DMF (2 mL) and water (0.4 mL). Add 30 (0.20 g), triphenylarsine (0.03 g), Pd(dppf)Cl₂ complex (0.022 g) and Cs₂CO₃ (0.36 g), wash in with DMF (1 mL) and heat at 60-70°C for 1 h. Workup in water with CH₂Cl₂ extractions, wash with water, dry, evaporate and pump at high vacuum and RT for 4 h. Isolate by preparative t.l.c. on silica, eluting with 1:1 hexanes-acetone to obtain 31 as a buff foam (0.16 g). HRMS: Found: 531.2655; MH⁺ requires 531.2641.

Step 3: Stir 31 (0.15 g) for 2 h. at RT in EtOAc (3 mL) and conc. HCl (0.7 mL) then dilute with water, discard the EtOAc phase, basify the aqueous phase with excess 2N NaOH and extract with several portions

15

of CH_2CI_2 . Dry over K_2CO_3 and evaporate to obtain the product **32** as a pale brown foam, suitable for subsequent reactions.

Step 4: Stir at RT for 5 h. a mixture of compound **32** (0.035 g), 4-fluoro-naphthoic acid (0.02 g), DMF (1.25 mL), HOBT (0.02 g), diisopropyl-ethylamine (0.05 g) and EDCI (0.04 g). Dilute with aqueous NaHCO₃, extract with CH_2CI_2 , dry over MgSO₄ and evaporate, then pump at high vacuum to remove residual DMF. Isolate the major product by preparative t.l.c. in acetone on silica, and convert the product to the

HCl salt as described in earlier preparations, to obtain the title

10 compound as a white powder (0.032 g).

Following the procedures of Examples 1 to 13, using the appropriate starting materials and modifications known to those skilled in the art, the additional compounds of the following structure were prepared

$$R-X-Q$$
 N
 N
 N
 R^{3}
 N
 N
 R^{5}

wherein R, X, Q, Y, R³ and R⁵ are as defined in the table

Ex.	R	Х	Q	Υ	R ³	R ⁵
14	н₃со√	-SO ₂ -	_(s)_	N	CH ₃ Ţ	CH ₃
15	H ₃ C	-SO ₂ -	Z Z	Ν	CH₃ ₩	CH ₃
16	H ₃ C	-SO ₂ -	Z =	N	CH ₃ ₩	€ à
17	H ₃ C	-SO ₂ -		N	CH₃ Ţ	
18	H ₃ C H ₃ C	-S-	N= N=	N	CH ₃ ₹	
19	H ₃ C	-SO ₂ -	~ <u>~</u>	N	CH₃ ₩	O NH ₂

	Γ	1		F		
20	H ₃ C H ₃ C	-S-	N=N N=N	СН	Н	
21	H ₃ C	-S-		N	CH ₃	
22	H ₃ C	-S-	~__\	Z	CH ₃ Ţ	O CH ₃
23	н₃со√_>	-SO ₂ -	~ N	СН	Н	O CH ₃
24	н₃со-{-}	-SO ₂ -	N N	СН	Н	O Br
25	H₃CO √	-SO ₂ -	~___	СН	Н	
26	H ₃ C H ₃ C	-S-	~ <u>N</u> =	СН	Н	
27	H ₃ C	-SO ₂ -	~ <u>``</u>	N	CH ₃	CH ₃ CH ₃ CH ₃
28		-SO ₂ -	N:N	Ν	H	HZ CH ₃ CH
29	H₃CO √	-SO ₂ -	~__	СН	Н	0
30	H ₃ C H ₃ C	-S-	-\(\sigma\)	N	Н	
31	н₃со√	-S-	√N:N	СН	Н	0
32	H ₃ C	-SO ₂ -	~__	Ν	CH ₃	Н
33	н₃со√	-S-	N=N	СН	Н	Н

	T	·		1		
34		-SO ₂ -	N:N	N	Н	CH ₃
35	H ₃ C H ₃ C	-O-	N=2	СН	Н	
36	H ₃ C H ₃ C	-S-	~	N	Н	CH ₃ CH ₃ CH ₃
37	H ₃ C H ₃ C	-S-	~__	СН	Н	
38		-SO ₂ -	~ <u>`</u>	СН	Н	CH ₃ CH ₃ CH ₃
39	CI	-SO ₂ -	~ <u>\</u>	СН	Н	Н
40	CI	-SO ₂ -	~~~	СН	Н	O NH ₂ CH ₃
41	CI	-SO ₂ -	~~~	СН	Н	O NH ₂
42	CI	-SO ₂ -	~__	СН	Н	O NH ₂ F
43	CI	-SO ₂ -	~___	СН	Н	O NH ₂ OCH ₃
44	CI	-SO ₂ -	~__	СН	Н	O NH ₂
45	cı	-SO ₂ -	N=>	СН	Н	O NH ₂
46_	CI	-SO ₂ -	~__	СН	Н	O NH ₂


47	н₃со-{_}	-SO ₂ -	~~~	СН	Н	CH ₃ CH ₃ CH ₃
48	н₃со-(}	-SO ₂ -		СН	Н	. Н -
49	н₃со-{_}	-SO ₂ -	z Z	СН	Н	NH2 F
50	н₃со√∑	-SO ₂ -	z	СН	Н	O NH ₂
51	н₃со√	-SO ₂ -	\rangle \ran	СН	I	O NH ₂
52		-SO ₂ -		T C	I	O NH ₂ F
53	н₃со-{-}	-SO ₂ -	Z	СН	Η	O NH ₂ CH ₃

Physical data for compounds 14-52 are shown in the table below:

Ex.	Physical Data
14	mp = 195-197°C (decomposition)
15	mp = 144-147°C (decomposition)
16	mp = 147-151°C (decomposition)
17	mp = 143-149°C (decomposition)
18	mp = above 136°C (decomposition)
19	mp = 134-137°C (decomposition)
20	HRMS found: 587.2250
21	HRMS found: 551.2851
22	HRMS found: 515.2848
23	HRMS found: 548.2575
24	HRMS found: 612.1517
25	HRMS found: 584.2596
26	HRMS found: 488.2739
27	HRMS found: 529.2840

28	HRMS found: 593.2546
29	mp = 144-149°C (decomposition)
30	mp = above 175°C (decomposition)
31	HRMS found: 537.2097 -
32	HRMS found: 429.2330
33	HRMS found: 399.2220
34	HRMS found: 552.1951
35	HRMS found: 473.2910
36	mp = above 250°C (decomposition)
37	mp = above 181°C (decomposition)
38	mp = 129-134°C
39	mp = above 182°C (decomposition)
40	mp = above 161°C (decomposition)
41	mp = above 109°C (decomposition)
42	mp = above 133°C (decomposition)
43	mp = above 139°C (decomposition)
44	mp = above 153°C (decomposition)
45	mp = above 155°C (decomposition)
46	mp = above 161°C (decomposition)
47	HRMS found: 530.2664
48	HRMS found: 430.2171
49	HRMS found: 567.2455
50	HRMS found: 583.2154
51	mp = above 165°C (decomposition)
52	HRMS found: 571.1939
53	HRMS found: 563.2712

Example 54



Step 1: A suspension of 6-chloronicotinic acid (5.0 g, 31.85 mmol) in CH₂Cl₂ (40 mL) containing DMF (0.2 mL) was treated with CICOCOCI

10

15

20

25

30

35

(3.3 mL, 38.22 mmol) and warmed to 40°C for two h. The resulting clear red solution was cooled to RT and the solvent removed *in vacuo*. The residue was dissolved in toluene and concentrated again to remove any unreacted CICOCOCI and traces of HCI. The resulting red gum was dissolved in CH₂Cl₂ (30mL). To this solution was added solid N,O-dimethyl hydroxylamine hydrochloride (4.66 g, 47.7 mmol) and iPr₂EtN (11 mL, 63.7 mmol). The reaction flask was capped and stirred overnight at RT. After extractive work-up and passage through a short column of silca gel, the Weinreb amide was obtained (5.7 g (yd: 89%)) as an amber syrup. TLC R_f = 0.5 in 25% EtOAc/CH₂Cl₂.

Step 2: CH₃MgBr (10 mL of a 3M soln.) was added dropwise to a solution of the product of Step 1 (5.7 g, 28 mmol) in 25 mL of dry THF at 0°C, generating a yellow precipitate. After stirring 1 h at RT, the reaction was quenched with saturated NH₄Cl solution and the product isolated by extracting with CH₂Cl₂. The product was purified by flash silica gel chromatography and isolated 3.7g (84%) as white solid. TLC: $R_f = 0.6$ in 25%EtOAc/CH₂Cl₂.

Step 3: A solution of the product of Step 2 (3.1 g, 20 mmol) and 3,4-methylenedioxyphenyl sulfinic acid sodium salt (4 g, 20 mmol) in dry DMF was heated near reflux for 16 h. The clear yellow solution turned turbid brown and the starting material was completely consumed. The reaction mixture was cooled to RT and quenched with water. Extraction with EtOAc gave 5 g of a dark yellow solid. The product was purified by flash silica gel chromatography and isolated as an off-white solid (3.1g; Yd: 50%). TLC $R_f = 0.4$ in 25% acetone-hexane.

Step 4: (S)-2-Methyl oxaborolidine (1M in toluene, 0.5 mL) was added to a solution of the product of Step 3 (0.75 g, 2.46 mmol) in 6 mL of CH_2Cl_2 and 2 mL of THF at RT. A solution of $(CH_3)_2S \cdot BH_3$ in THF (2M, 0.74 mL) was introduced dropwise over 4 minutes. After stirring at RT for 1 h, the reaction was quenched with CH_3OH and volatiles were removed *in vacuo*. The residue was dissolved in 20 mL of CH_2Cl_2 and processed through aqueous extractive work-up to obtain a yellow solid. The product was purified by flash silicagel chromatography to obtain the pure chiral alcohol as a white foamy solid (0.66 g, 88%). TLC: $R_f = 0.3$ in 25% acetone-hexane.

30

Step 5: Et₃N (4 mmol, 0.55 mL) and CH₃SO₂Cl (2.6 mmol; 0.2 mL) were added in sequence to a solution of the product of Step 4 (0.6 g; 1.95 mmol) in 5 mL of CH₂Cl₂ at 0°C. After stirring and gradual warming to RT over 1.5 h., the reaction mixture was diluted with 10 mL of CH₂Cl₂ and subjected to an aqueous work-up to remove most of the by-5 products. Concentration in vacuo gave 0.72 g (96%) of the mesylate as a dark yellow gum. This was redissolved in dry CH3CN (8 mL) and treated with 1-(1-tertbutoxycarbonyl-piperidin-4-yl)-3(R)-methylpiperazine (0.566 g, 2 mmol) and 2,2,6,6-tetramethyl piperidine (0.33 mL) and refluxed for 8 hours. The reaction mixture was cooled to RT and 10 quenched with water. Extractive work-up in CH2Cl2 provided 1 g of a crude product, which was purified by flash silica gel chromatography using 25% acetone in CH₂Cl₂ to obtain an intermediate (S,R-diastereomer) as white foamy solid (0.7 g, Yd. = 70%) and its R,R-diastereomer (0.1 g, Yd. = 10%). TLC: $R_f = 0.55$ for S,R-isomer and 0.4 for 15 the R.R-isomer in 25% acetone-CH₂Cl₂. Step 6: The product of Step 6 (S,R) was converted to its free base form by treatment with TFA in CH2Cl2 followed by basic extractive work-up to obtain the free piperazino-piperidine as a white foamy solid. To a

(0.020 g, 0.15 mmol), 2-amino-3-methyl-benzoic acid (0.031g; 0.2 mmol) and iPr₂Et₂N (0.035 mL, 0.2 mmol). After stirring at RT for 10 to 16 h, the reaction mixture was diluted with excess CH₂Cl₂ and washed with water,
10% citric acid, 10% NaOH solution and brine. The resulting crude product was purified by flash chromatography to obtain the free base form of the title compound as a colorless film (0.055 g, Yd. = 91%). Treatment with 1M HCl in Et₂O converted it to the HCl salt. mp 180-182°C.

Using a similar procedure and the appropriate acid, the following compounds are prepared:

solution of the free piperazino-piperidine (0.048 g, 0.1 mmol) in CH₂Cl₂

(1 mL) were added in sequence: EDCI (0.029 g, 0.15 mmol), HOBT

wherein R⁵ is as defined in the table

Ex.	R ⁵	Melting Point
55	r√o F	172-174°C
56	NH ₂	184-186°C
57	ST O NH ₂	187-188°C
58		174°C
59	H_3C CH_3	165°C

Examples 60 and 60A

5 Reaction scheme:

- **Step 1**: The procedure of Example 5, step 2, was used for the preparation of **33** using intermediate **11** (7.93 ml), 9-BBN (92 ml), 2,5-dibromopyridine (10 g), DMF (95 ml), H_2O (9.1 ml), K_2CO_3 (7.62 g) and $Pd(dppf)Cl_2$ (1.03 g). After purification, **33** was isolated as a solid (14.3 g) in 96% yield, mp 66°C.
- **Step 2**: NaH (1.01 g of a 60% dispersion in oil) was washed with hexane (6.0 ml), N,N-dimethyl acetamide (8.4 ml) was added, the resulting mixture was cooled in an ice bath and 3-chlorothiophenol (2.94 ml) was added dropwise. After stirring at RT for 15 min, **33** (3.00 g) and
- 10 Cul (4.82 g) were added all at once and the resulting mixture was heated at 120°C for 12 h and then at 140°C for 4 h. After cooling to RT, EtOAc (150 ml) was added, the mixture was filtered and rinsed with EtOAc. The combined EtOAc portions were washed with water and brine, dried over MgSO₄, filtered and evaporated to give a crude oil
- 15 (4.77 g) which was further purified by column chromatography (silica adsorbent; 225 g; 1:8 EtOAc:hexanes; 1:4 EtOAc:hexanes; 1:2 EtOAc:hexanes as eluant). After evaporation of the appropriate fractions, **34** (1.87 g) was isolated as a waxy solid in 53 % yield.
- Step 3: 34 (1.00 g) was dissolved in CH₂Cl₂ (24 ml), the resulting solution was cooled to 0°C, and then mCPBA (1.21 g) was added over 10 min. The resulting mixture was stirred at RT for 24 h. Two new components were noted by TLC analysis (2:1 hexanes:EtOAc). The reaction mixture was diluted with CH₂Cl₂, made basic (pH=11) with 2 N NaOH and the CH₂Cl₂ layer was removed. The organic layer was
- washed with water and brine, dried over MgSO₄, filtered and evaporated to give an oil (700 mg) which was further purified by column chromatography (silica adsorbent; 1:8 EtOAc:hexanes; 1:4 EtOAc:hexanes; 1:2 EtOAc:hexanes as eluant). After evaporation of the appropriate fractions, the less polar component, **35A**, (196 mg) was isolated as a foam in 18 % yield. The more polar component **35B** (339)
- isolated as a foam in 18 % yield. The more polar component, **35B** (339 mg) was isolated as a white foam in 35 % yield.
 - Step 4: The intermediate 35A was treated as in Example 5, steps 3 and 4, to obtain the compound of Example 60.
- Step 5: The compound of Example 60 was treated as in Example 5, step 5, followed by the procedure of Example 13, step 4, using 2-amino

3-methyl benzoic acid in place of 4-fluoronaphthoic acid to obtain the compound of **Example 60A**. After work up and purification, **60A** (15 mg) was isolated in its free base form as a foam in 54 % yield. HRMS: calc'd: $M'H^+$: $C_{30}H_{35}N_4O_3SCI$: 567.2197; measured: 567.2189.

5

Reaction scheme:

10

Intermediate **35B** was treated in the same manner as **35A** to give, initially, the compound of **Example 61** (48 % over 2 steps from **35B**) and then **Example 61A** (20 % over 3 steps) in hydrochloride form, as a white solid. mp: decompostion above 151°C

What is Claimed:

1. A compound having the structural formula

$$R-X-Q$$

$$R^{1}$$

$$R^{2}$$

$$Z$$

$$R^{4}$$

5 including all stereoisomers and pharmaceutically acceptable salts and solvates thereof,

wherein one of Y and Z is -N- and the other is -N- or -CH-;

X is -O-, -S-, -SO-, -SO₂- or -CH₂-;

$$Q is \begin{cases} -\sqrt{N} - \frac{1}{2}, \frac{1}{2} - \frac{1}{2} \\ -\sqrt{N} - \frac{1}{2} \end{cases}$$
 or
$$\begin{cases} -\sqrt{N} - \frac{1}{2} \\ -\sqrt{N} - \frac{1}{2} \end{cases}$$

R is (C₁-C₂₀)alkyl, (C₃-C₁₂)cycloalkyl, aryl, R⁸-aryl or heteroaryl; R¹, R² and R³ are independently selected from the group consisting of H and (C₁-C₂₀)alkyl;

 R^4 is (C_1-C_{20}) alkyl, (C_3-C_{12}) cyclolalkyl or

 $\begin{array}{lll} & R^5 \text{ is H, } (C_1\text{-}C_{20}) alkyl, \text{-}C(O)(C_1\text{-}C_{20}) alkyl, } R^9\text{-}arylcarbonyl, \\ & -SO_2(C_1\text{-}C_{20}) alkyl, } R^9\text{-}arylsulfonyl \text{-}C(O)O(C_1\text{-}C_{20}) alkyl, } R^9\text{-}aryloxy-carbonyl, \text{-}C(O)NH-(C_1\text{-}C_{20}) alkyl } \text{ or } R^9\text{-}arylaminocarbonyl; \\ \end{array}$

 R^6 is H or (C_1-C_{20}) alkyl;

 R^7 is H, $(\mathsf{C}_1\text{-}\mathsf{C}_{20})$ alkyl, hydroxy $(\mathsf{C}_1\text{-}\mathsf{C}_{20})$ alkyl or $(\mathsf{C}_1\text{-}\mathsf{C}_{20})$ -

20 alkoxy(C_1 - C_{20})alkyl;

 R^8 is 1-3 substituents independently selected from the group consisting of H, (C_1-C_{20}) alkyl, halogen, hydroxy, (C_1-C_{20}) alkoxy or hydroxy(C_1-C_{20})alkyl, or two adjacent R^8 groups may be joined to form a (C_1-C_2) alkylenedioxy group; and

- R⁹ is 1-3 substituents independently selected from the group consisting of H, (C_1-C_{20}) alkyl, halogen, amino or (C_1-C_{20}) alkylamino.
 - A compound of claim 1 wherein Z is N.
- 30 3. A compound of claim 1 wherein R is 3,4-methylenedioxyphenyl, 3-methylphenyl, 3-chlorophenyl or 4-methoxyphenyl.

- 4. A compound of claim 1 wherein X is -CH₂- or -SO₂-.
- 5. A compound of claim 1 wherein R^1 and R^2 are each H and R^3 is H or CH_3 .

6. A compound of claim 1 wherein R4 is

wherein R⁷ is H or CH₃; R⁶ is H: and R⁵ is R⁹-arylcarbonyl.

- 7. A compound of claim 6 wherein R⁵ is R⁹-(1-naphthyl)-C(O)-, o-toluoyl-C(O)- or 2-aminophenyl-C(O)-.
 - 8. A compound as defined in claim 1 selected from the group consisting of

15

- 9. A pharmaceutical composition comprising an effective amount of a compound as defined in claim 1 in combination with a
 5 pharmaceutically acceptable carrier.
 - 10. The use of a compound of claim 1 for the preparation of a medicament for treating a cognitive or neurodegenerative disease in a mammal in need thereof.

AMENDED CLAIMS

[received by the International Bureau on 19 November 1999 (19.11.99); original claim 1 amended; remaining claims unchanged (1 page)]

A compound having the structural formula

$$R-X-Q \xrightarrow{R^1 R^2} Z \xrightarrow{R^4}$$

5 including all stereoisomers and pharmaceutically acceptable salts and solvates thereof,

wherein one of Y and Z is -N- and the other is -N- or -CH-;

 $X \text{ is -O-, -S-, -SO-, -SO}_2\text{- or -CH}_2\text{-;}$

R is (C_1-C_{20}) alkyl, (C_3-C_{12}) cycloalkyl, aryl, R^8 -aryl or heteroaryl;

 R^{1} , R^{2} and R^{3} are independently selected from the group consisting of H and $(C_{1}-C_{20})$ alkyl;

R⁴ is (C₃-C₁₂)cyclolalkyl or

15 R⁵ is H, (C_1-C_{20}) alkyl, $-C(O)(C_1-C_{20})$ alkyl, R⁹-arylcarbonyl, $-SO_2(C_1-C_{20})$ alkyl, R⁹-arylsulfonyl $-C(O)O(C_1-C_{20})$ alkyl, R⁹-aryloxy-carbonyl, $-C(O)NH-(C_1-C_{20})$ alkyl or R⁹-arylaminocarbonyl;

 R^6 is H or (C_1-C_{20}) alkyl;

 R^7 is H, (C_1-C_{20}) alkyl, hydroxy (C_1-C_{20}) alkyl or (C_1-C_{20}) -alkoxy (C_1-C_{20})

20 C_{20})alkyl;

 R^8 is 1-3 substituents independently selected from the group consisting of H, (C_1-C_{20}) alkyl, halogen, hydroxy, (C_1-C_{20}) alkoxy or hydroxy(C_1-C_{20})alkyl, or two adjacent R^8 groups may be joined to form a (C_1-C_2) alkylenedioxy group; and

- 25 R⁹ is 1-3 substituents independently selected from the group consisting of H, (C₁-C₂₀)alkyl, halogen, amino or (C₁-C₂₀)alkylamino.
 - 2. A compound of claim 1 wherein Z is N.
- 30 3. A compound of claim 1 wherein R is 3,4-methylenedioxyphenyl, 3-methylphenyl, 3-chlorophenyl or 4-methoxyphenyl.

INTERNATIONAL SEARCH REPORT

Inter onal Application No PCT/US 99/12821

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER C07D401/12	01/14 C07D409/12 A61	K31/445			
According to	o International Patent Classification (IPC) or to both national class	sification and IPC				
B. FIELDS	SEARCHED					
Minimum do IPC 7	ocumentation searched (classification system followed by classifi ${\tt C07D-A61K}$	ication symbols)				
Documentat	tion searched other than minimum documentation to the extent th	nat such documents are included in the fields	searched -			
Electronic d	lata base consulted during the international search (name of data	a base and, where practical, search terms us	ed)			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to claim No.			
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLOHIO, US KAMIYA, SHOZO ET AL: "Synthese: 4-alkylaminomethylpyridazines" retrieved from STN Database accession no. 79:9213: XP002116719 3-ethoxy-6'(4-methyl-1-piperid pyridazine (RN=49631-25-6) -& CHEMICAL ABSTRACTS, vol. 79 15 October 1973 (1973-10-15) Columbus, Ohio, US; abstract no. 92138, XP002116718 & CHEM. PHARM. BULL. (1973), 2 1510-15,	s of 3- and 8 inyl)methyl! , no. 15,	1,5			
X Furt	ther documents are listed in the continuation of box C.	X Patent family members are list	ed in annex.			
° Special ca	ategories of cited documents : nent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	"T" later document published after the interpretation or priority date and not in conflict with cited to understand the principle or invention	vith the application but theory underlying the			
filling date cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone which is cited to establish the publication date of another "Y" document of particular relevance: the claimed invention						
"O" docum	citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "D" document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.					
later t	nent published prior to the international filing date but than the priority date claimed	"&" document member of the same pate				
	e actual completion of the international search	Date of mailing of the international	search report			
2	28 September 1999	12/10/1999				
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer				
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nt, Fax: (+31-70) 340-3016	De Jong, B				

1

INTERNATIONAL SEARCH REPORT

Inter onal Application No
PCT/US 99/12821

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	[m]	lo.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N	10.
A	WO 96 26196 A (SCHERING CORP) 29 August 1996 (1996-08-29) cited in the application claim 1	1,9,10	
			-
			-

1

INTERNATIONAL SEARCH REPORT

formation on patent family members

Inter onal Application No
PCT/US 99/12821

			1
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9626196	A 29-08-1996	AU 701452 B AU 4971796 A CA 2212895 A EP 0811002 A FI 973446 A JP 11501014 T US 5883096 A US 5889006 A ZA 9601293 A	28-01-1999 11-09-1996 29-08-1996 10-12-1997 22-10-1997 26-01-1999 16-03-1999 30-03-1999 -